Srivicha KrudsoodSamir N. PatelNopaddon TangpukdeeWipa ThanachartwetWattana LeowattanaKarnchana PornpininworakijAndrea K. BoggildSornchai LooareesuwanKevin C. KainToronto General HospitalMahidol University2018-08-242018-08-242007-04-01American Journal of Tropical Medicine and Hygiene. Vol.76, No.4 (2007), 655-658000296372-s2.0-34249698953https://repository.li.mahidol.ac.th/handle/20.500.14594/24565A combination of atovaquone-proguanil (Malarone®; GlaxoSmithKline, Research Triangle Park, NC) was previously shown to be highly effective in the treatment of uncomplicated Plasmodium falciparum malaria. However, there are only limited recent efficacy data, particularly from regions of multidrug resistance. In this study, we examined the efficacy of atovaquone-proguanil for the treatment of uncomplicated P. falciparum malaria on the Thailand-Myanmar border. Patients were given directly observed atovaquone-proguanil (1,000 mg/400 mg) once a day for three days and followed-up for four weeks in a non-transmission area. Of 140 eligible patients enrolled in this open-label study, 97.8% (95% confidence interval = 95.4-100%) responded to therapy and remained clear of parasitemia at follow-up. Mean parasite clearance time was 41.9 hours and mean fever clearance time was 37.1 hours. On the basis of genotyping, three cases of treatment failure were identified (1 RIII and 2 RI). These data indicate that atovaquone-proguanil remains highly efficacious for the treatment of multidrug-resistant P. falciparum malaria in Thailand. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.video/youtubeMahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS